Uninfected HeLa cells were incubated in the presence of 10 μM compound D7 or DMSO, and cell density was assessed at 0, 22, 44 and 66 hours using a spectrophotometric assay. Compound D7 had little or no effect on HeLa cell growth rate compared to DMSO (fig. 4A). We also examined cell cytotoxicity at these times using an adenylate kinase release assay. Compound D7 exhibited the same level of cytotoxicity as DMSO at 0, 22 and 44 hours, and only slightly higher cytotoxicity levels
at 66 hr compared to DMSO-exposed cells (fig. 4B). Therefore compound D7 had little or no effect on HeLa cell viability and the this website inhibitory effect of D7 on chlamydial growth is not likely due to a non-specific cytotoxic effect on the host cell. Figure 4 Compound D7 does not reduce Silmitasertib cost HeLa cell viability. A: subconfluent HeLa www.selleckchem.com/products/Neratinib(HKI-272).html cell monolayers incubated in MEM containing either DMSO (0.1%) or compound D7 (10 μM) with 2 μg/mL cycloheximide (+), were collected by trypsinization and the cell density was measured by absorbance at 800 nM at the times indicated. Compound D7 did not significantly alter HeLa cell number compared to DMSO alone. B: cell culture supernatant adenylate kinase activity from the samples in (A).
Exposure of HeLa cells to 10 μM compound D7 for 44 hours was not more cytotoxic than cells exposed to DMSO. At 66 hours there was a small increase in HeLa cell release of adenylate kinase in the D7-exposed group. Error bars represent means plus 2 standard deviations. Compound D7 does not block activation of the MEK/ERK pathway It has been shown previously that activation of the MEK/ERK pathway is necessary for chlamydial invasion of host cells  and sustained activation of this pathway is required for acquisition of host glycerophospholipids by Chlamydia
. To rule out the possibility that the inhibitory effect of compound D7 on C. pneumoniae growth could be due to an inhibition of the MEK/ERK pathway we assessed the level of ERK1 and ERK2 (p44/p42 MAP kinase, respectively) phosphorylation in the presence of compound D7. HeLa cells exposed to either 10 or 100 μM of compound D7 contained high levels of phosphorylated p44 and p42 MAP kinase following EGF stimulation. HeLa cells exposed to 10 or 25 μM U0126, a specific inhibitor of MEK1/2, were used as control and did not contain phosphorylated p44 or p42 MAP kinase following EGF stimulation (fig. Carteolol HCl 5). This result demonstrates that compound D7 does not block phosphorylation of p44/p42 MAP kinase in HeLa cells, suggesting that chlamydial growth inhibition caused by D7 was not due to a non-specific blockage of the MEK/ERK pathway. Figure 5 Compound D7 does not block activation of the MEK/ERK pathway in EGF-stimulated HeLa cells. HeLa cells incubated with DMSO, compound D7 or U0126 were activated with EGF and the levels of MAP kinase phosphorylation were determined by Western blot using anti-phospho ERK1/2 antibody. Compound D7 at 10 and 100 μM, and DMSO at 0.